← Back to Search

PD-L1 Inhibitor

SGN-PDL1V for Advanced Solid Tumors

START Madrid-CIOCC_Hospital HM Sanchinarro, Madrid, Spain
Targeting 7 different conditionsSGN-PDL1VPhase 1RecruitingResearch Sponsored by Seagen Inc.

Study Summary

This trial will test the safety of a new drug for solid tumors. It will also study side effects. The study has three parts and will enroll participants who have metastatic or unresectable solid tumors.

Eligible Conditions
  • Esophageal Cancer
  • Squamous Cell Carcinoma
  • Ovarian Tumors
  • Melanoma
  • Breast Cancer
  • Non-Small Cell Lung Cancer

Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below
Your disease has come back after treatment, has not responded to treatment, or you cannot tolerate the approved treatments.
You must have a certain level of PD-L1 expression based on past testing.
The disease can be measured using specific guidelines at the start of the study.
You must have been diagnosed with advanced non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, or triple negative breast cancer.
Participants with head and neck cancer must have a confirmed diagnosis through tissue or cell tests.
You should have a good ability to carry out daily activities without feeling limited by your health.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to approximately 3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to approximately 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of participants with DLTs by dose level
Number of participants with adverse events (AEs)
Number of participants with dose-limiting toxicities (DLTs)
+1 more
Secondary outcome measures
Duration of objective response per RECIST v1.1 by investigator assessment
Incidence of anti-drug antibodies (ADAs)
Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) by investigator assessment
+5 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: SGN-PDL1VExperimental Treatment1 Intervention
SGN-PDL1V monotherapy

Find a Location

Who is running the clinical trial?

Seagen Inc.Lead Sponsor
202 Previous Clinical Trials
68,100 Total Patients Enrolled
Andres Forero-Torres, MDStudy DirectorSeagen Inc.
3 Previous Clinical Trials
227 Total Patients Enrolled

Media Library

SGN-PDL1V (PD-L1 Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05208762 — Phase 1
Esophageal Cancer Research Study Groups: SGN-PDL1V
Esophageal Cancer Clinical Trial 2023: SGN-PDL1V Highlights & Side Effects. Trial Name: NCT05208762 — Phase 1
SGN-PDL1V (PD-L1 Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05208762 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the Food and Drug Administration accorded approval to SGN-PDL1V?

"Our team at Power believes that SGN-PDL1V is relatively safe, rating it a 1 on the scale. This assessment is based upon its status as an early phase trial, with limited efficacy and safety data available."

Answered by AI

Are there any locations in North America where this clinical investigation is taking place?

"At present, this clinical trial is enrolling participants at NEXT Oncology in Fairfax, Virginia; The University of Texas MD Anderson Cancer Center in Houston, Texas; and South Texas Accelerated Research Therapeutics in San Antonio, Utah. There are also 5 additional sites offering this medication."

Answered by AI

Is this investigation open to recruitment?

"Affirmative. All information found on clinicaltrials.gov confirms that this medical experiment, which was initially declared on the 25th of October 2022, is still looking for participants. It requires 315 people to join from 5 distinct healthcare centres."

Answered by AI

To what extent are participants engaging in this investigation?

"Affirmative, the information on clinicaltrials.gov reveals that this study is currently seeking individuals to enroll in their trial. Initially posted October 25th 2022 and last modified November 11th 2022, this research needs 315 participants from 5 different sites."

Answered by AI

What therapeutic objectives are the researchers hoping to realize with this clinical trial?

"This study will last approximately one month and its primary outcome is the number of participants with adverse events. Secondary objectives include overall survival, objective response rate per RECIST v1.1 by investigator assessment, and pharmacokinetic parameters such as apparent terminal half-life."

Answered by AI
~181 spots leftby Jul 2025